Lysine 50 of Tat regulates expression of C5, CRLF2, APBA1, and BDNF genes. by Loreto Carvallo (4167607)

“…<p>THP-1Tat-Flag and THP-1Tat K50ATat-Flag cell lines (generated from independent experiments described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0179882#pone.0179882.g005" target="_blank">Fig 5</a>) were differentiated to macrophages with PMA for 24 and 48 hours. …”

Specific inhibition of host p38α MAPK leads to a minor decrease in epithelial cell invasion. by Françoise I. Bussière (692733)

Activation of NMDA receptors with D-serine obviously limited the decrease of p-CREB in the hippocampus of the surviving LPS-treated mice. by Shuibing Zhang (4336402)

NbUCH15 promotes RipE1 stability by deubiquitination. by Wenjia Yu (9422059)

Arsenic exposure decreases zinc and calcium in embryos and zinc deficiency and arsenic effects <i>zip1</i>, <i>znt7</i> and <i>zip8</i> mRNA levels. by Laura M. Beaver (115507)

Mean positional maternal haemodynamics by individual. by Laura Ormesher (17131361)

Nicotine decreased Akt phosphorylation in SK-BR-3 cells. by Masanori A. Murayama (5774585)

<i>P</i>. <i>caudatum</i> grazing of <i>E</i>. <i>coli</i> O157:H7 EDL933 and cattle commensal <i>E</i>. <i>coli</i> (186) over three days at ambient laboratory temperature. by Carrie E. Schmidt (2174290)

(A) Decreasing CaMKII activity by KN-93 (high-3 µmol/L, low-0.5 µmol/L), AIP (high-10 µmol/L, low-2 µmol/L), or decreasing calmodulin activity by W-7 (high-50 µmol/L, low-20 µmol/L) decreases spontaneous AP firing rate (n = 10 for each drug), cAMP (n = 4 for each drug) and ATP (n = 5 for each drug). by Yael Yaniv (162548)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Leucine gavage, but not KIC, increases glutamate levels in the gastrocnemius and EDL muscle, and decreases isoleucine levels in the EDL muscle. by Gagandeep Mann (19452744)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Lung and heart eNOS and iNOS mRNA. by Devi Ganesh (3176385)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)